Trial Profile
A Randomized Crossover Phase II Study of Gemcitabine and Carboplatin With or Without MK-0646 as First-Line Therapy in Advanced Squamous Non-Small Cell Lung Carcinoma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dalotuzumab (Primary) ; Carboplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 11 Aug 2009 New trial record